Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced new clinical results ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types EVOLUTION 3 feasibility study demonstrates improved time in range using ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Insulet has reported results from two clinical studies, STRIVE and EVOLUTION 3, assessing its upcoming Omnipod 6 automated insulin delivery (AID) system and a fully closed-loop (FCL) solution for ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Insulet (PODD) has been back in focus after new clinical data on its investigational Omnipod ...

Insulet Corporation (NASDAQ: PODD) is one of the best NASDAQ stocks with high upside potential. On June 6, Insulet announced promising new clinical trial results for its next-generation tubeless ...

On a promising note, management expects CGM to return to double-digit growth in the second quarter. The Libre portfolio, Abbott’s flagship CGM franchise, is used by more than 8 million people across ...

This week's Android headlines; Samsung Galaxy Z Flip8 specs, Galaxy A27 release, Oppo Pad Mini launched, more Magic V6 awards ...